Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CD5 Chimeric Antigen Receptors (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Malignancies: a Multi-center, Open-label, Non-randomized, Phase 1/2 Clinical Trial

NCT06316856 is registered in ClinicalTrials.gov with Beijing GoBroad Hospital as lead sponsor.

NCT NCT06316856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06316856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CD5 Chimeric Antigen Receptors (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Malignancies: a Multi-center, Open-label, Non-randomized, Phase 1/2 Clinical Trial
Lead sponsor
Beijing GoBroad Hospital
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 18, 2024
Completion date
December 30, 2026
Enrollment
54 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, in relapse, refractory acute lymphoblastic leukemia, t-cell acute lymphocytic leukemia, t-cell malignancies